{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:06:31Z","timestamp":1784577991771,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019746","name":"Sunnybrook Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jad.2026.122056","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:16:36Z","timestamp":1780067796000},"page":"122056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A more optimistic outlook about disease-modifying therapies and depressive symptoms in multiple sclerosis: A cross-sectional analysis"],"prefix":"10.1016","volume":"412","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-3232","authenticated-orcid":false,"given":"David E.","family":"Freedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Feinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.122056_bb0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.msard.2017.07.008","article-title":"Systematic review of depression in patients with multiple sclerosis and its relationship to interferon\u03b2 treatment","volume":"17","author":"Alba Pal\u00e9","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jad.2026.122056_bb0010","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurology(R) Neuroimmunol. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.jad.2026.122056_bb0015","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.biopsych.2023.11.010","article-title":"Mapping the relationship of white matter lesions to depression in multiple sclerosis","volume":"95","author":"Baller","year":"2024","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122056_bb0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in Multiple Sclerosis: a systematic review and meta-analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.jad.2026.122056_bb0030","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00415-017-8642-5","article-title":"Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)","volume":"264","author":"Comi","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jad.2026.122056_bb0035","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ibneur.2024.04.002","article-title":"Longitudinal determinants of employment status in people with relapsing-remitting multiple sclerosis","volume":"16","author":"van Egmond","year":"2024","journal-title":"IBRO Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.jad.2026.122056_bb0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.genhosppsych.2007.08.002","article-title":"Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis","volume":"30","author":"Ehde","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2026.122056_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.jad.2026.122056_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1176\/appi.neuropsych.20240096","article-title":"Predictors of antidepressant use among people with multiple sclerosis","volume":"37","author":"Freedman","year":"2025","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"13","key":"10.1016\/j.jad.2026.122056_bb0055","first-page":"6018","article-title":"The association between fingolimod and mental health outcomes in a cohort of Multiple Sclerosis patients with stress","volume":"27","author":"Gammoh","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jad.2026.122056_bb0060","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.msard.2018.09.008","article-title":"Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: a systematic review","volume":"26","author":"Gasim","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.jad.2026.122056_bb0065","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/j.jad.2026.122056_bb0070","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1177\/1352458509347150","article-title":"Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients","volume":"15","author":"Honarmand","year":"2009","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"issue":"7","key":"10.1016\/j.jad.2026.122056_bb0075","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/13524585221148144","article-title":"Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort","volume":"29","author":"Hu","year":"2023","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.jad.2026.122056_bb0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jns.2016.03.024","article-title":"Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial","volume":"365","author":"Hunter","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jad.2026.122056_bb0085","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1212\/WNL.0000000000011242","article-title":"Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years","volume":"96","author":"Kalincik","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jad.2026.122056_bb0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fneur.2015.00097","article-title":"Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis","volume":"6","author":"Kunkel","year":"2015","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.jad.2026.122056_bb0095","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jad.2026.122056_bb0100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000334722","article-title":"Natalizumab may improve cognition and mood in multiple sclerosis","volume":"67","author":"Lang","year":"2012","journal-title":"Eur. Neurol."},{"issue":"1","key":"10.1016\/j.jad.2026.122056_bb0105","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41598-018-21243-x","article-title":"Prevalence of depression in the community from 30 countries between 1994 and 2014","volume":"8","author":"Lim","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jad.2026.122056_bb0110","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/13524585211031128","article-title":"Risk of depression in multiple sclerosis across disease-modifying therapies","volume":"28","author":"Longinetti","year":"2022","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"issue":"6","key":"10.1016\/j.jad.2026.122056_bb0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17582024.2025.2520709","article-title":"A drug evaluation narrative review of cladribine as a treatment for multiple sclerosis","volume":"15","author":"Martin","year":"2025","journal-title":"Neurodegener. Dis. Manag."},{"issue":"6","key":"10.1016\/j.jad.2026.122056_bb0120","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1037\/0022-006X.69.6.942","article-title":"Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis","volume":"69","author":"Mohr","year":"2001","journal-title":"J. Consult. Clin. Psychol."},{"issue":"11","key":"10.1016\/j.jad.2026.122056_bb0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1177\/1352458511411061","article-title":"Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study","volume":"17","author":"Montalban","year":"2011","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"issue":"4","key":"10.1016\/j.jad.2026.122056_bb0130","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jpsychores.2012.08.004","article-title":"Multiple sclerosis relapses and depression","volume":"73","author":"Moore","year":"2012","journal-title":"J. Psychosom. Res."},{"issue":"8","key":"10.1016\/j.jad.2026.122056_bb0135","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/medicina61081409","article-title":"Depression, anxiety, and MSQOL-54 outcomes in RRMS patients receiving fingolimod or cladribine: a cross-sectional comparative study","volume":"61","author":"\u00d6zbek","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"13","key":"10.1016\/j.jad.2026.122056_bb0140","doi-asserted-by":"crossref","first-page":"e1322","DOI":"10.1212\/WNL.0000000000012610","article-title":"Interface of multiple sclerosis, depression, vascular disease, and mortality: a population-based matched cohort study","volume":"97","author":"Palladino","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jad.2026.122056_bb0145","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.jad.2026.122056_bb0150","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.0000000000004411","article-title":"Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis","volume":"89","author":"Rossi","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jad.2026.122056_bb0155","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1176\/ajp.147.11.1493","article-title":"Antidepressant pharmacotherapy of depression associated with multiple sclerosis","volume":"147","author":"Schiffer","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122056_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s44220-022-00002-y","article-title":"Lesion network localization of depression in multiple sclerosis","volume":"1","author":"Siddiqi","year":"2023","journal-title":"Nat. Ment. Health"},{"issue":"6","key":"10.1016\/j.jad.2026.122056_bb0165","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13548506.2014.999810","article-title":"Resilience, self-efficacy, coping styles and depressive and anxiety symptoms in those newly diagnosed with multiple sclerosis","volume":"20","author":"Tan-Kristanto","year":"2015","journal-title":"Psychol. Health Med."},{"issue":"7","key":"10.1016\/j.jad.2026.122056_bb0170","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","volume":"45","year":"1995","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jad.2026.122056_bb0175","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jad.2026.122056_bb0180","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.jad.2026.122056_bb0185","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1177\/1352458520958369","article-title":"Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype","volume":"27","author":"Zhang","year":"2021","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"issue":"6","key":"10.1016\/j.jad.2026.122056_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:00:54Z","timestamp":1784577654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726009080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S0165032726009080"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122056","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A more optimistic outlook about disease-modifying therapies and depressive symptoms in multiple sclerosis: A cross-sectional analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122056"}}